(-)-Epigallocatechin 3-gallate (EGCG) at the ocular surface inhibits corneal neovascularization

Medical Hypotheses

Volumn 76, Issue 3, 2011, Pages 311-313

  Sanchez Huerta V ^a   Gutierrez Sanchez L ^a   Flores Estrada, J ^a,b  

^a Asociacion para Evitar la Ceguera en Mexico IAP   (Mexico)

^b HOSPITAL JUÁREZ DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CURCUMIN; EPIGALLOCATECHIN GALLATE; GELATINASE A; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CHEMOPROPHYLAXIS; CORNEA NEOVASCULARIZATION; DRUG SAFETY; GENOTOXICITY; HYPOTHESIS; INFLAMMATION; LONG TERM CARE; NONHUMAN; TEA; TRANSCRIPTION INITIATION;

ANIMALS; CATECHIN; CORNEAL NEOVASCULARIZATION; EYE; HUMANS; INTERLEUKIN-1BETA; NF-KAPPA B; TRANSCRIPTION FACTOR RELA; VISION, OCULAR;

EID: 79751535141     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.09.020     Document Type: Article

References (28)

1. Chang J.H., Gabison E.E., Kato T., Azar D.T. Corneal neovascularization. Curr Opin Ophthalmol 2001, 12:242-249.
2. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 2007, 92:50-57.
3. Ebrahem Q., Chaurasia S.S., Vasanji A., et al. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 2010, 176:496-503.
4. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:264-302.
5. Lu P., Li L., Liu G., Zhang X., Mukaida N. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 2009, 50:4761-4768.
6. Kondo Y., Fukuda K., Adachi T., Nishida T. Inhibition by a selective IkappaB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture. Invest Ophthalmol Vis Sci 2008, 49:4850-4857.
7. Castro M.R., Lutz D., Edelman J.L. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 2004, 79:275-285.
8. Valcic S., Muders A., Jacobsen N.E., Liebler D.C., Timmermann B.N. Antioxidant chemistry of green tea catechins. Identification of products of the reaction of (-)-epigallocatechin gallate with peroxyl radicals. Chem Res Toxicol 1999, 12:382-386.
9. Donà M., Dell'Aica I., Calabrese F., et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 2003, 170:4335-4341.
10. Fujiki H. Green tea: health benefits as cancer preventive for humans. Chem Rec 2005;5:119-32.
11. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 2007, 26:373S-388S.
12. Shimizu M., Shirakami Y., Moriwaki H. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 2008, 9:1034-1049.
13. Sen T., Moulik S., Dutta A., et al. Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci 2009, 84:194-204.
14. Rodriguez S.K., Guo W., Liu L., Band M.A., Paulson E.K., Meydani M. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 2006, 118:1635-1644.
15. Kim S.J., Jeong H.J., Lee K.M., et al. Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 2007, 18:587-596.
16. Singh R., Ahmed S., Islam N., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 2002, 46:2079-2086.
17. Yang J., Wei D., Liu J. Repressions of MMP-9 expression and NF-kappa B localization are involved in inhibition of lung carcinoma 95-D cell invasion by (-)-epigallocatechin-3-gallate. Biomed Pharmacother 2005, 59:98-103.
18. Sugisawa A., Umegaki K. Physiological concentrations of (-)-epigallocatechin-3-O-gallate (EGCG) prevent chromosomal damage induced by reactive oxygen species in WIL2-NS cells. J Nutr 2002, 132:1836-1839.
19. Isbrucker R.A., Edwards J.A., Wolz E., Davidovich A., Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparation. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006, 44:636-650.
20. Joussen A.M., Rohrschneider K., Reichling J., Kirchhof B., Kruse F.E. Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids. Exp Eye Res 2000, 71:483-487.
21. Bian F., Zhang M.C., Zhu Y. Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo. Ophthalmologica 2008, 222:178-186.
22. Cao Y., Cao R. Angiogenesis inhibited by drinking tea. Nature 1999, 398:381.
23. Nakao S., Hata Y., Miura M., et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007, 171:1058-1065.
24. Comstock T.L., Holland E.J. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opin Pharmacother 2010, 11:843-852.
25. Koenig Y., Bock F., Horn F., Kruse F., Straub K., Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009, 247:1375-1382.
26. DeStafeno J.J., Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007, 125:834-836.
27. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008, 99:1501-1506.
28. Abdulrazik M., Tamilvanan S., Benita S. Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study. J Drug Target 2006, 14:670-679.